Health Canada has granted a Notice of Compliance for Fabhalta (iptacopan capsules), the first oral monotherapy treatment for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. In clinical trials, treatment with Fabhalta offered superior haemoglobin improvement in the absence of red blood cell (RBC) transfusions. Complement Component C5 is a gene that […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!